Stock listing
NASDAQ:APRE Aprea Therapeutics, Inc. Stock
Home listing (NASDAQ) of Aprea Therapeutics, Inc.
Follow Aprea Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:APRE
$0.491 USD +0.006 (+1.3%)
Close on Nov 2, 2026
- Day range
- $0.488 – $0.520 USDNov 2, 2026
- Volume
- 88,988 sharesNov 2, 2026
- Market cap
- $6.18M USDAt the close on Nov 2, 2026 · price × 12.59M shares outstanding
- 52-week range
- $0.410 – $1.490 USDLowest and highest trades, Nov 3, 2025 – Nov 2, 2026
- Traded on an average day
- $239,832 USDMedian day 130,055 shares · last 3 months, Aug 3, 2026 – Nov 2, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:APRE · Home | $0.491 USD | +0.006 (+1.3%) | 88,988 | $0.500 | $0.520 | $0.488 | $0.485 | Close on Nov 2, 2026 |
Daily closes
Last 3 months, Aug 3, 2026 – Nov 2, 2026 · NASDAQ:APRE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.491 | +0.006 | +1.3% | $0.500 | $0.520 | $0.488 | 88,988 | |
| $0.485 | -0.009 | -1.8% | $0.479 | $0.521 | $0.460 | 167,609 | |
| $0.494 | -0.044 | -8.2% | $0.540 | $0.540 | $0.486 | 171,488 | |
| $0.538 | +0.025 | +4.8% | $0.512 | $0.540 | $0.512 | 147,494 | |
| $0.513 | +0.064 | +14.3% | $0.436 | $0.536 | $0.429 | 187,886 | |
| $0.449 | -0.069 | -13.3% | $0.520 | $0.520 | $0.410 | 568,600 | |
| $0.518 | -0.024 | -4.4% | $0.527 | $0.546 | $0.495 | 89,183 | |
| $0.542 | -0.019 | -3.3% | $0.559 | $0.559 | $0.511 | 130,055 | |
| $0.560 | -0.001 | -0.2% | $0.564 | $0.600 | $0.511 | 81,622 | |
| $0.561 | +0.029 | +5.4% | $0.545 | $0.567 | $0.511 | 366,946 | |
| $0.532 | -0.052 | -8.9% | $0.603 | $0.605 | $0.530 | 201,065 | |
| $0.584 | -0.034 | -5.5% | $0.658 | $0.658 | $0.573 | 160,100 | |
| $0.618 | +0.035 | +6.0% | $0.580 | $0.626 | $0.580 | 65,400 | |
| $0.583 | -0.017 | -2.8% | $0.611 | $0.611 | $0.582 | 74,300 | |
| $0.600 | +0.007 | +1.2% | $0.610 | $0.648 | $0.593 | 136,900 | |
| $0.593 | -0.011 | -1.8% | $0.610 | $0.615 | $0.581 | 116,500 | |
| $0.604 | +0.046 | +8.2% | $0.557 | $0.607 | $0.557 | 70,400 | |
| $0.558 | -0.047 | -7.8% | $0.605 | $0.610 | $0.550 | 239,400 | |
| $0.605 | -0.031 | -4.9% | $0.636 | $0.638 | $0.576 | 249,900 | |
| $0.636 | -0.040 | -5.9% | $0.680 | $0.680 | $0.634 | 198,900 | |
| $0.676 | -0.019 | -2.7% | $0.686 | $0.695 | $0.640 | 296,500 | |
| $0.695 | -0.029 | -4.0% | $0.716 | $0.736 | $0.685 | 862,200 | |
| $0.724 | -0.026 | -3.5% | $0.764 | $0.782 | $0.675 | 779,600 | |
| $0.750 | -0.020 | -2.6% | $0.780 | $0.820 | $0.741 | 581,700 | |
| $0.770 | +0.018 | +2.4% | $0.758 | $0.820 | $0.750 | 591,600 | |
| $0.752 | -0.009 | -1.2% | $0.760 | $0.771 | $0.740 | 69,800 | |
| $0.761 | -0.019 | -2.4% | $0.780 | $0.780 | $0.741 | 53,300 | |
| $0.780 | 0.000 | 0.0% | $0.800 | $0.800 | $0.765 | 52,000 | |
| $0.780 | +0.048 | +6.6% | $0.742 | $0.810 | $0.742 | 282,000 | |
| $0.732 | -0.005 | -0.7% | $0.760 | $0.760 | $0.700 | 189,600 | |
| $0.737 | -0.023 | -3.0% | $0.760 | $0.760 | $0.730 | 96,700 | |
| $0.760 | +0.010 | +1.3% | $0.780 | $0.780 | $0.740 | 80,000 | |
| $0.750 | +0.019 | +2.6% | $0.750 | $0.772 | $0.730 | 117,200 | |
| $0.731 | -0.018 | -2.4% | $0.729 | $0.757 | $0.711 | 186,000 | |
| $0.749 | -0.032 | -4.1% | $0.820 | $0.820 | $0.733 | 184,200 | |
| $0.781 | +0.007 | +0.9% | $0.771 | $0.843 | $0.760 | 120,300 | |
| $0.774 | -0.015 | -1.9% | $0.796 | $0.820 | $0.765 | 127,300 | |
| $0.789 | -0.002 | -0.3% | $0.781 | $0.810 | $0.781 | 61,300 | |
| $0.791 | -0.044 | -5.3% | $0.850 | $0.871 | $0.783 | 134,700 | |
| $0.835 | +0.041 | +5.2% | $0.840 | $0.880 | $0.779 | 317,800 | |
| $0.794 | -0.012 | -1.5% | $0.800 | $0.809 | $0.791 | 89,400 | |
| $0.806 | -0.014 | -1.7% | $0.820 | $0.820 | $0.780 | 111,700 | |
| $0.820 | -0.016 | -1.9% | $0.810 | $0.854 | $0.799 | 168,800 | |
| $0.836 | +0.036 | +4.5% | $0.780 | $0.900 | $0.780 | 462,400 | |
| $0.800 | -0.039 | -4.6% | $0.845 | $0.852 | $0.780 | 476,000 | |
| $0.839 | -0.021 | -2.4% | $0.880 | $0.910 | $0.820 | 344,000 | |
| $0.860 | -0.120 | -12.2% | $0.990 | $0.990 | $0.810 | 1,182,000 | |
| $0.980 | +0.030 | +3.2% | $1.090 | $1.160 | $0.923 | 2,818,700 | |
| $0.950 | +0.145 | +18.0% | $0.815 | $0.990 | $0.802 | 2,148,900 | |
| $0.805 | +0.165 | +25.8% | $0.704 | $0.850 | $0.680 | 2,803,200 | |
| $0.640 | 0.000 | 0.0% | $0.657 | $0.670 | $0.623 | 14,600 | |
| $0.640 | -0.031 | -4.6% | $0.672 | $0.693 | $0.633 | 38,900 | |
| $0.671 | -0.001 | -0.1% | $0.695 | $0.710 | $0.668 | 52,700 | |
| $0.672 | -0.018 | -2.6% | $0.706 | $0.706 | $0.672 | 10,400 | |
| $0.690 | +0.010 | +1.5% | $0.679 | $0.719 | $0.670 | 49,500 | |
| $0.680 | +0.009 | +1.3% | $0.689 | $0.695 | $0.657 | 15,800 | |
| $0.671 | -0.012 | -1.8% | $0.671 | $0.682 | $0.656 | 21,300 | |
| $0.683 | +0.023 | +3.5% | $0.780 | $0.780 | $0.656 | 28,200 | |
| $0.660 | +0.016 | +2.5% | $0.671 | $0.700 | $0.655 | 24,200 | |
| $0.644 | -0.006 | -0.9% | $0.660 | $0.686 | $0.639 | 30,800 | |
| $0.650 | +0.017 | +2.7% | $0.635 | $0.670 | $0.601 | 38,400 | |
| $0.633 | +0.012 | +1.9% | $0.613 | $0.652 | $0.613 | 22,600 | |
| $0.621 | +0.022 | +3.7% | $0.619 | $0.630 | $0.600 | 67,500 | |
| $0.599 | +0.001 | +0.2% | $0.613 | $0.625 | $0.599 | 67,900 | |
| $0.598 | -0.022 | -3.5% | $0.603 | $0.658 | $0.590 | 152,300 |
- Ticker
- NASDAQ:APRE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 16, 2026
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 26 slides
Latest news
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Oct 16, 2026
Closed $0.584 (-5.5%) on Oct 16, 2026
Aprea Therapeutics to Present at October Conferences
Oct 5, 2026
Closed $0.676 (-2.7%) on Oct 5, 2026
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Sep 22, 2026
Closed $0.732 (-0.7%) on Sep 22, 2026
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Aug 28, 2026
Closed $0.839 (-2.4%) on Aug 28, 2026
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Aug 12, 2026
Closed $0.683 (+3.5%) on Aug 12, 2026
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
Jul 30, 2026
Closed $0.635 (+2.3%) on Jul 30, 2026
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Jun 1, 2026
Closed $0.816 (-8.6%) on Jun 1, 2026
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
Closed $0.88 (-2.2%) on May 13, 2026
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
Apr 1, 2026
Closed $0.704 (-7.7%) on Apr 1, 2026
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
Mar 30, 2026
Closed $0.739 (+8.2%) on Mar 30, 2026
Decks
Investor Presentation (August 2026)
Investor deck · 26 slides · August 2026
Investor Presentation (May 2026)
Investor deck · 26 slides · May 13, 2026
Investor Presentation (March 2026)
Investor deck · 28 slides · Mar 30, 2026
Investor Presentation (March 2026)
Investor deck · 27 slides · Mar 16, 2026
Aprea Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 20 in the last 12 months · 96 in all · newest Oct 16, 2026 · oldest 2019
- Decks
- 36 decks · latest August 2026
Where Aprea Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:APRE · Home listing · This page | NASDAQ | United States | USD |
| BOATS:APRE | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Aprea Therapeutics, Inc.